Solventum (NYSE:SOLV – Get Free Report) is one of 510 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Solventum to similar businesses based on the strength of its earnings, institutional ownership, valuation, analyst recommendations, dividends, profitability and risk.
Earnings & Valuation
This table compares Solventum and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Solventum | $8.32 billion | $1.56 billion | 94.70 |
| Solventum Competitors | $1.89 billion | $137.31 million | 5.94 |
Solventum has higher revenue and earnings than its rivals. Solventum is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Solventum has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Solventum’s rivals have a beta of 2.57, suggesting that their average stock price is 157% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Solventum and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Solventum | 1 | 3 | 9 | 1 | 2.71 |
| Solventum Competitors | 4330 | 10559 | 18358 | 840 | 2.46 |
Solventum presently has a consensus price target of $90.27, suggesting a potential upside of 7.11%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 29.03%. Given Solventum’s rivals higher possible upside, analysts clearly believe Solventum has less favorable growth aspects than its rivals.
Profitability
This table compares Solventum and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Solventum | 1.91% | 25.03% | 8.65% |
| Solventum Competitors | -191.42% | -197.86% | -21.83% |
Institutional & Insider Ownership
40.3% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 0.2% of Solventum shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Solventum beats its rivals on 9 of the 13 factors compared.
About Solventum
Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
